PRESTIGE CONSUMER HEALTHCARE INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $76.62 per share for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-06-30 was $74.48, a 26.00% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-06-30 was $59.11, a 7.75% increase year-over-year.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-06-30 was $54.86.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2021-06-30 was $36.45.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2026 was $76.62, a 25.87% increase from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $60.87, a 12.41% increase from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $54.15, a 9.33% increase from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $49.53, a 30.93% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-03-31 | $76.62 10-K · filed 2026-05-14 | |||
| 2025-12-31 | $76.52 10-Q · filed 2026-02-05 | |||
| 2025-09-30 | $76.13 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $74.48 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $60.87 10-K · filed 2026-05-14 | |||
| 2024-12-31 | $60.87 10-Q · filed 2026-02-05 | |||
| 2024-09-30 | $60.87 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $59.11 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $54.15 10-K · filed 2026-05-14 | |||
| 2023-12-31 | $54.15 10-Q · filed 2025-02-06 | |||
| 2023-09-30 | $54.81 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $54.86 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $49.53 10-K · filed 2025-05-09 | |||
| 2022-12-31 | $49.53 10-Q · filed 2024-02-08 | |||
| 2022-03-31 | $37.83 10-K · filed 2024-05-15 | |||
| 2021-12-31 | $37.83 10-Q · filed 2023-02-02 | |||
| 2021-09-30 | $37.83 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $36.45 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $34.65 10-K · filed 2023-05-05 | |||
| 2020-12-31 | $0.00 10-Q · filed 2022-02-03 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | |||
| 2020-03-31 | $32.62 10-K · filed 2022-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |